Bringing Precision Medicine to Rheumatology
Johns Hopkins includes precision medicine in its mission, a mission that, according to Dr. Albayda, calls for better and better phenotyping.
“In the end, rarity doesn’t make a disease more complex or less understandable,” says Dr. Albayda.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Knowing the phenotype may help clinicians in practice. In the case of anti-SAE dermatomyositis, rheumatologists may expect to find a disease dominated by skin rashes, with sometimes milder muscle and lung disease.
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
References
- Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in U.K. Caucasian adult-onset myositis. Ann Rheum Dis. 2009 Oct;68(10):1621–1625.
- Ge Y, Lu X, Shu X, et al. Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts. Sci Rep. 2017 Mar 15;7(1):188.
- Betteridge Z, Tansley S, Shaddick G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun. 2019 Jul;101:48–55.
- Albayda J, Mecoli C, Casciola-Rosen L, et al. A North American cohort of anti-SAE dermatomyositis: Clinical phenotype, testing, and review of cases. ACR Open Rheumatol. 2021 May;3(5):287–295.
